Edition:
United States

Rhythm Pharmaceuticals Inc (RYTM.OQ)

RYTM.OQ on NASDAQ Stock Exchange Global Market

32.60USD
15 Jun 2018
Change (% chg)

$-0.17 (-0.52%)
Prev Close
$32.77
Open
$33.26
Day's High
$33.30
Day's Low
$31.91
Volume
104,404
Avg. Vol
31,874
52-wk High
$34.99
52-wk Low
$16.89

Chart for

About

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent,... (more)

Overall

Beta: --
Market Cap(Mil.): $897.48
Shares Outstanding(Mil.): 27.53
Dividend: --
Yield (%): --

Financials

  RYTM.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -1.77 -- --
ROI: -56.26 -5.87 13.17
ROE: -59.93 -7.71 15.15

BRIEF-Rhythm Pharmaceuticals Q1 Loss Per Share $0.60

* RHYTHM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 14 2018

BRIEF-Rhythm Pharma Announces Licensing Agreement With Takeda

* RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME

Apr 02 2018

BRIEF-Rhythm Pharmaceuticals Reports Qtrly Loss Per Share $0.41‍​

* RHYTHM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide

* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY

Jan 04 2018

Earnings vs. Estimates